Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Bulletin of the World Health Organization
|
March 31, 2012
Putting the priorities first: medicines for maternal and child health
Suzanne R Hill
BMC Medicine
|
February 3, 2012
Cost-effectiveness analysis for clinicians
Suzanne R Hill
Pharmacoeconomics
|
September 25, 2014
NICE, social values, and balancing objectivity and equity
Suzanne R Hill, Leslie G Olson
Trends in Pharmacological Sciences
|
December 3, 2014
Fair and reasonable judgments of cost-effectiveness of medicines
Leslie G Olson, Suzanne R Hill
Bulletin of the World Health Organization
|
November 21, 2007
Setting standards for essential children's medicines
Suzanne R Hill, Andy Gray, Martin Weber
Pharmacoeconomics
|
December 23, 2017
Value-Based Pricing: L'Enfant Terrible?
Sarah Garner, Andrew Rintoul, Suzanne R Hill
Bulletin of the World Health Organization
|
December 21, 2016
Clarifying WHO's position on the FRAX® tool for fracture prediction
Nathan Ford, Susan L Norris, Suzanne R Hill
JAMA Network Open
|
January 16, 2019
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
Kiu Tay-Teo, André Ilbawi, Suzanne R Hill
JAMA
|
November 24, 2005
Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme
David A Henry, Suzanne R Hill, Anthony Harris
Bulletin of the World Health Organization
|
July 1, 2009
A comparison of two methods for measuring anti-hypertensive drug use: concordance of use with South African standard treatment guidelines
Thamizhanban Pillay, Anthony J Smith, Suzanne R Hill
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Bulletin of the World Health Organization
|
March 31, 2012
Putting the priorities first: medicines for maternal and child health
Suzanne R Hill
BMC Medicine
|
February 3, 2012
Cost-effectiveness analysis for clinicians
Suzanne R Hill
Pharmacoeconomics
|
September 25, 2014
NICE, social values, and balancing objectivity and equity
Suzanne R Hill, Leslie G Olson
Trends in Pharmacological Sciences
|
December 3, 2014
Fair and reasonable judgments of cost-effectiveness of medicines
Leslie G Olson, Suzanne R Hill
Bulletin of the World Health Organization
|
November 21, 2007
Setting standards for essential children's medicines
Suzanne R Hill, Andy Gray, Martin Weber
Pharmacoeconomics
|
December 23, 2017
Value-Based Pricing: L'Enfant Terrible?
Sarah Garner, Andrew Rintoul, Suzanne R Hill
Bulletin of the World Health Organization
|
December 21, 2016
Clarifying WHO's position on the FRAX® tool for fracture prediction
Nathan Ford, Susan L Norris, Suzanne R Hill
JAMA Network Open
|
January 16, 2019
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
Kiu Tay-Teo, André Ilbawi, Suzanne R Hill
JAMA
|
November 24, 2005
Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme
David A Henry, Suzanne R Hill, Anthony Harris
Bulletin of the World Health Organization
|
July 1, 2009
A comparison of two methods for measuring anti-hypertensive drug use: concordance of use with South African standard treatment guidelines
Thamizhanban Pillay, Anthony J Smith, Suzanne R Hill
Page
of 3